Intermedin inhibits macrophage foam-cell formation via tristetraprolin- mediated decay of CD36 mRNA

Cardiovascular Research

Volumn 101, Issue 2, 2014, Pages 297-305

  Dai, Xiao Yan ^a   Cai, Yan ^a   Sun, Weiliang ^a   Ding, Yanhong ^a   Wang, Wengong ^a   Kong, Wei ^a   Tang, Chaoshu ^a   Zhu, Yi ^a   Xu, Ming Jiang ^a   Wang, Xian ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Atherosclerosis; Macrophage; mRNA degradation; Peptide; Scavenger receptor

Indexed keywords

CD36 ANTIGEN; INTERMEDIN; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; SHORT HAIRPIN RNA; TRISTETRAPROLIN;

3' UNTRANSLATED REGION; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; AU RICH ELEMENT; CELL MATURATION; CONTROLLED STUDY; FOAM CELL; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN RNA BINDING; RNA DEGRADATION;

ATHEROSCLEROSIS; MACROPHAGE; MRNA DEGRADATION; PEPTIDE; SCAVENGER RECEPTOR;

3' UNTRANSLATED REGIONS; ANIMALS; ANTIGENS, CD36; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BINDING SITES; CELLS, CULTURED; CHOLESTEROL; DISEASE MODELS, ANIMAL; FOAM CELLS; LIPOPROTEINS, LDL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUROPEPTIDES; PHOSPHORYLATION; RNA INTERFERENCE; RNA STABILITY; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TRISTETRAPROLIN;

EID: 84893129997     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt254     Document Type: Article

References (42)

1. Watanabe T, Sato K, Itoh F,Wakabayashi K, Shichiri M, Hirano T. Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease. Sensors (Basel) 2012;12:4974-4985
2. Cai Y, Xu MJ, Teng X, Zhou YB, Chen L, Zhu Y et al. Intermedin inhibits vascular calcification by increasing the level of matrix gamma-carboxyglutamic acid protein. Cardiovasc Res 2010;85:864-873
3. Dai XY,Cai Y, Mao DD, Qi YF, Tang C, XuQet al. Increased stability of phosphatase and tensin homolog by intermedin leading to scavenger receptor A inhibition of macrophages reduces atherosclerosis in apolipoprotein E-deficient mice. J Mol Cell Cardiol 2012;53:509-520
4. Roh J, Chang CL, Bhalla A, Klein C, Hsu SY. Intermedin is a calcitonin/calcitonin gene-related peptide family peptide acting through the calcitonin receptor-like receptor / receptor activity-modifying protein receptor complexes. J Biol Chem 2004;279: 7264-7274
5. Takei Y, Hyodo S, Katafuchi T, Minamino N. Novel fish-derived adrenomedullin in mammals: Structure and possible function. Peptides 2004;25:1643-1656
6. KunjathoorVV, Febbraio M, Podrez EA,Moore KJ, Andersson L, Koehn S et al. Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-49988
7. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-337
8. Febbraio M, Guy E, Silverstein RL. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis. Arteriosc Thromb Vasc Biol 2004;24:2333-2338
9. Febbraio M, Podrez EA, Smith JD, HajjarDP, Hazen SL, Hoff HFet al. Targeted disruption of the class B scavenger receptorCD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000;105:1049-1056
10. Makinen PI, Lappalainen JP, Heinonen SE, Leppanen P, Lahteenvuo MT, Aarnio JV et al. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc Res 2010;88: 530-538
11. Geloen A, Helin L, Geeraert B, Malaud E, Holvoet P, Marguerie G. CD36 inhibitors reduce postprandial hypertriglyceridemia and protect against diabetic dyslipidemia and atherosclerosis. PLoS One 2012;7:e37633
12. Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, Ochoa-Herrera J, Perez-Lopez P, Pulido-Moran M et al. Squalene ameliorates atherosclerotic lesions through the reduction ofCD36scavenger receptor expression in macrophages. Mol Nutr Food Res 2012;56: 733-740
13. Tang FT, Cao Y,Wang TQ, Wang LJ, Guo J, Zhou XS et al. Tanshinone IIA attenuates atherosclerosis in ApoE(2/2) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol 2011;650:275-284
14. Chang N, Yi J, Guo G, Liu X, Shang Y, Tong T et al. HuR uses AUF1 as a cofactor to promote p16INK4 mRNA decay. Mol Cell Biol 2010;30:3875-3886
15. Zhao G, Xu MJ, Zhao MM, Dai XY, Kong W, Wilson GM et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int 2012;82:34-44
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275
17. Lu KY, Ching LC, Su KH, Yu YB, Kou YR, Hsiao SH et al. Erythropoietin suppresses the formation of macrophage foam cells: Role of liverXreceptor alpha. Circulation 2010;121: 1828-1837
18. Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte / macrophage differentiation and uptake of oxidized LDL. Cell 1998;93:241-252
19. Frasca D, Landin AM, Alvarez JP, Blackshear PJ, Riley RL, Blomberg BB. Tristetraprolin, a negative regulator ofmRNAstability, is increased in old B cells and is involved in the degradation of E47 mRNA. J Immunol 2007;179:918-927
20. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: Beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006;26:1702-1711
21. Hirose T, Totsune K, Mori N, Morimoto R, Hashimoto M, Nakashige Y et al. Increased expression of adrenomedullin 2/intermedin in rat hearts with congestive heart failure. Eur J Heart Fail 2008;10:840-849
22. Totsune K, Takahashi K, Mackenzie HS, Murakami O, Arihara Z, Sone M et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptoractivity modifying protein (RAMP)2 and calcitonin-receptor- like receptor (CRLR) in the hearts of rats with congestive heart failure. Clin Sci (Lond) 2000;99:541-546
23. Teng X, Bian Y, Cai Y, Duan X, Yuan F, Du J et al. Downregulation of endogenous intermedin augmented myocardial injury in rats ischemic/reperfusion. Horm Metab Res 2013; 45:206-212
24. Chang CL, Roh J, Hsu SY. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: A comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides 2004;25:1633-1642
25. Takei Y, Inoue K, Ogoshi M, Kawahara T, Bannai H, Miyano S. Identification of novel adrenomedullin inmammals: A potent cardiovascular and renal regulator. FEBS Lett 2004;556: 53-58
26. Yuan Y,Wang X, Zeng Q,WuHM, Qi YF, Tang CS. Effects of continuous intermedin infusion onblood pressure and hemodynamic function in spontaneously hypertensive rats. J Geriatr Cardiol 2012;9:17-27
27. Zhang X,GuL,Chen X,Wang S, Deng X, LiuK et al. Intermedin ameliorates atherosclerosis in apoE null mice by modifying lipid profiles. Peptides 2012;37:189-193
28. Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: Macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005;2:309-315
29. de Winther MP, Gijbels MJ, van DijkKW, van Gorp PJ, suzuki H, Kodama T et al. Scavenger receptor deficiency leads to more complex atherosclerotic lesions in APOE3Leiden transgenic mice. Atherosclerosis 1999;144:315-321
30. Sakaguchi H, Takeya M, Suzuki H, Hakamata H, Kodama T, Horiuchi S et al. Role of macrophage scavenger receptors in diet-induced atherosclerosis in mice. Lab Invest 1998;78:423-434
31. Babaev VR, Gleaves LA, Carter KJ, Suzuki H, Kodama T, Fazio S et al. Reduced atherosclerotic lesions in mice deficient for total or macrophage-specific expression of scavenger receptor-A. Arterioscler Thromb Vasc Biol 2000;20:2593-2599
32. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386:292-296
33. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM Jr, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 2004;109:790-796
34. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 1998;281:1001-1005
35. Cao H, Deterding LJ, Venable JD, Kennington EA, Yates JR III, Tomer KB et al. Identification of the anti-inflammatory protein tristetraprolin as a hyperphosphorylated protein by mass spectrometry and site-directed mutagenesis. Biochem J 2006;394:285-297
36. Carballo E, Cao H, Lai WS, Kennington EA, Campbell D, Blackshear PJ. Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. J Biol Chem 2001;276:42580-42587
37. Chrestensen CA, Schroeder MJ, Shabanowitz J, HuntDF, PeloJW, WorthingtonMTet al. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 2004;279:10176-10184
38. Stoecklin G, Stubbs T, Kedersha N,Wax S, Rigby WF, Blackwell TK et al. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 2004;23:1313-1324
39. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D et al. Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 2004; 113:764-773
40. Griffin E, Re A, Hamel N, Fu C, Bush H, McCaffrey T et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat Med 2001;7:840-846
41. Fukuhara-Takaki K, Sakai M, Sakamoto Y, Takeya M, Horiuchi S. Expression of class A scavenger receptor is enhanced by high glucose in vitro and under diabetic conditions in vivo: One mechanism for an increased rate of atherosclerosis in diabetes. J Biol Chem 2005;280:3355-3364
42. Aono J, Suzuki J, Iwai M, Horiuchi M, Nagai T, Nishimura K et al. Deletion of the angiotensin II type 1a receptor prevents atherosclerotic plaque rupture in apolipoprotein E2/2 mice. Arterioscler Thromb Vasc Biol 2012;32:1453-1459